About: Tratamiento Hipolipemiante En La Era Covid-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Tratamiento Hipolipemiante En La Era Covid-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Tratamiento Hipolipemiante En La Era Covid-19
Creator	Covid-19, Era Díaz Fernández, Beatriz Díaz Rodríguez, Mscángel Díaz Rodríguez, Ángel Frías Vargas, Manuel Hipolipemiante, Tratamiento La, En Vargas, Manuel
Source	Elsevier; Medline; PMC
abstract	Resumen Antecedentes y objetivos: La pandemia por COVID-19 ha puesto de manifiesto que las enfermedades cardiovasculares conllevan mayor riesgo de mortalidad. Han surgido dudas en cuanto la terapia lipídica en estos pacientes. Nuestro objetivo en esta revisión es analizar la eficacia y seguridad de la terapia hipolipemiante en los pacientes con COVID-19. Material y métodos: Se realizó una revisión de la literatura científica en PubMed, informes CDC, NIH y NCBI SARS-CoV-2 utilizando las palabras claves: COVID-19, statins, ezetimibe, PCSK9 inhibitors, hypercholesterolemia and hypolipidemic drugs. Resultados: Las estatinas se deben seguir utilizando en los pacientes con COVID-19 en base a su eficacia, seguridad, efectos inmunosupresores, antiinflamatorios disponibilidad y accesibilidad. En función de los niveles de riesgo cardiovascular de estos pacientes, puede ser necesario el empleo de estatinas de alta potencia y/o ezetimiba y/o inhibidores de la proproteína convertasa subtilisina (iPCSK9) en pacientes de alto y muy alto riesgo cardiovascular. Los pacientes tratados con iPCSK9 deben seguir con el tratamiento por sus efectos beneficiosos sobre la prevención de la enfermedad cardiovascular. Los pacientes con hipercolesterolemia familiar y COVID-19 son especialmente vulnerables a la enfermedad cardiovascular precoz y deben seguir recibiendo el tratamiento hipolipemiante intensivo. Conclusiones: En los pacientes con COVID-19, la mayoría de las enfermedades cardiovasculares basales son de origen aterosclerótico, con peor pronóstico para los pacientes con alto riesgo y muy alto riesgo de enfermedad cardiovascular. En estos pacientes, el tratamiento intensivo con estatinas y/o combinación fija con ezetimiba y/o iPCSK9 juega un papel fundamental. Abstract Background and objectives: The COVID-19 pandemic has shown that cardiovascular diseases carry a higher risk of mortality. Doubts have been raised regarding lipid therapy in these patients. The objectives are to analyze the efficacy and safety of lipid lowering therapy in patients with COVID-19 Material and Methods: A review of the scientific literature was conducted in PubMed, CDC Reports, NIH, and NCBI SARS-CoV-2 using the keywords: COVID-2; statins; ezetimibe; PCSK9 inhibitors; hypercholesterolemia; and hypolipidemic drugs. Results: The stations should continue to use patients with COVID-19 based on their efficacy, safety, immunosuppressive effects, anti-inflammatory availability and accessibility. Depending on the cardiovascular risk levels of these patients, the use of high potency statins and / or ezetimibe and / or iPCSK9 may be necessary in patients with high and very high cardiovascular risk. Patients treated with iPCSK9 should continue treatment for its beneficial effects in preventing cardiovascular disease. Patients with familial hypercholesterolemia and COVID-19 are especially vulnerable to cardiovascular disease and should continue to receive severe lipid lowering therapy. Conclusions: In patients with COVID-19, the majority of baseline CVDs are of atherosclerotic origin, with the worst prediction for patients with high risk and very high risk of CVD. In these patients, intensive treatment with statins and / or fixed combination with ezetimibe and / or iPCSK9 plays a fundamental role.
has issue date	2020-07-01(xsd:dateTime)
bibo:doi	10.1016/j.semerg.2020.06.014
bibo:pmid	32718781
has license	els-covid
sha1sum (hex)	c7862d0ecae6fa5323d4eb9c013f856d9c7a8af5
schema:url	https://doi.org/10.1016/j.semerg.2020.06.014
resource representing a document's title	Tratamiento Hipolipemiante En La Era Covid-19
has PubMed Central identifier	PMC7328617
has PubMed identifier	32718781
schema:publication	Semergen
resource representing a document's body	covid:c7862d0ecae6fa5323d4eb9c013f856d9c7a8af5#body_text
is schema:about of	named entity 'COVID-19' named entity 'Journal' named entity 'COVID-19' named entity 'pandemia' named entity 'COVID-19' named entity 'hace' named entity 'LDL' named entity 'virus' named entity 'PubMed' named entity 'LDL' named entity 'LDL' named entity 'cardiovascular' named entity 'ACE2' named entity 'COVID' named entity 'COVID' named entity 'coronavirus' named entity 'COVID-19 pandemic' named entity 'mg/dl' named entity 'SARS-CoV-2' named entity 'hacer' named entity 'virus' named entity 'COVID' named entity 'cardiovascular disease' named entity 'statins' named entity 'MYD88' named entity 'infección' named entity 'tocilizumab' named entity 'la entrada' named entity 'COVID' named entity 'COVID' named entity 'CDC' named entity 'remdesivir' named entity 'COVID-19' named entity 'hypercholesterolemia' named entity 'usan' named entity 'coronavirus' named entity 'infección' named entity 'IBV' named entity 'hypolipidemic' named entity 'ECA2' named entity 'lopinavir/ritonavir' named entity 'PCSK9' named entity 'statins' named entity 'hypolipidemic' named entity 'COVID' named entity 'Claves' named entity 'como' named entity 'coronavirus' named entity 'immunosuppressive' named entity 'atherosclerotic' named entity 'coronavirus' named entity 'statins' named entity 'lipid' named entity 'COVID' named entity 'familial hypercholesterolemia' named entity 'intensive treatment' named entity 'cardiovascular' named entity 'anti-inflammatory' named entity 'puede ser' named entity 'potency' named entity 'PubMed' named entity 'CVD' named entity 'NF-kB' named entity 'cardiovascular risk' named entity 'hypercholesterolemia' named entity 'CVDs' named entity 'coronavirus' named entity 'virus' named entity 'cardiovascular' named entity 'SARS-CoV-2' named entity 'cardiovascular risk' named entity 'infección' named entity 'COVID-19' named entity 'cardiovascular'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software